Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C24H28N8O2 |
Molar mass | 460.542 g·mol−1 |
3D model (JSmol) | |
| |
|
Gusacitinib (ASN002) is an investigational drug which acts as a pan-Janus kinase inhibitor, binding with similar affinity at JAK1, JAK2, JAK3 and TYK2, and also inhibiting spleen tyrosine kinase (SYK).[1] It is taken orally and was developed for the treatment of eczema and dermatitis.[2][3][4]